Nimbus Synergies Inc.

Nimbus Synergies leads early-stage investments in Canadian health-technology companies from pre-seed through Series A. It typically writes first cheques of $250K–$2M for 10–20% ownership, targets companies with $500K–$2M ARR and $5M–$20M pre-money valuations, and excludes therapeutics and Class III medical devices.